Small Molecules Disrupt PTPσ-TrkA Interaction for Nerve Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to promote nerve regeneration across chondroitin sulfate proteoglycan (CSPG)-containing scars, such as those formed after myocardial infarction, due to the inhibitory interactions between CSPGs and neuronal protein tyrosine phosphatase receptor sigma (PTPσ), which prevent sympathetic nerve reinnervation and lead to arrhythmias and cardiac dysfunction.
Innovation Solution
Development of small molecules like HJ-01 and HJ-02 that disrupt the interaction between PTPσ and tropomyosin receptor kinases (Trks), specifically TrkA, allowing for sympathetic axon outgrowth and nerve regeneration into cardiac scars by preventing PTPσ-mediated inhibition of Trk signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If CSPGs are present in the cardiac scar to provide structural support and prevent tissue breakdown, then scar stability is improved, but nerve regeneration is inhibited due to PTPσ-CSPG interactions
Solution Approach 1:
The patent extracts the harmful interaction between PTPσ and CSPGs by introducing small molecules that specifically bind to PTPσ, removing its inhibitory effect on nerve regeneration while preserving the structural role of CSPGs in the scar matrix
Solution Approach 2:
Small molecule compounds act as intermediaries that bind to PTPσ and prevent its interaction with CSPGs and Trk receptors, thereby mediating between the scar matrix and nerve regeneration processes without disrupting scar stability
2Reliability
If PTPσ is allowed to interact with Trk receptors to maintain normal receptor function, then receptor signaling is preserved, but axon outgrowth is suppressed due to dephosphorylation of Trk
Solution Approach 1:
The patent changes the phosphorylation state parameter of Trk receptors by blocking PTPσ-mediated dephosphorylation, thereby shifting the balance from suppression to promotion of axon outgrowth while maintaining receptor signaling capability
3Reliability
If early treatment with small molecules is administered to promote nerve regeneration, then regenerative outcome is improved, but treatment timing window is limited as efficacy decreases after three days post-MI
Solution Approach 1:
The patent applies preliminary action by administering small molecules early in the post-MI period (within three days) to prevent the establishment of strong PTPσ-CSPG interactions and create a permissive environment for subsequent nerve regeneration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HJ-01 and HJ-02 restore sympathetic nerve innervation, reduce arrhythmia susceptibility, and surprisingly decrease infarct size and improve cardiac output even when treatment begins three days after myocardial infarction, demonstrating their effectiveness in promoting nerve regeneration and cardiac protection.
Implementation Method 1
small molecules (HJ-01 and HJ-02) that do not inhibit PTPσ activity, but instead disrupt the interaction between PTPσ and TrkA
Implementation Method 2
In sympathetic nerves Nerve Growth Factor (NGF) activation of TrkA stimulates axon extension, while dephosphorylation of TrkA suppresses axon growth
Implementation Method 3
PTPσ binds to and dephosphorylates Trk receptors, thus inhibiting their kinase activity
Data Source
AI summary
The present invention concerns novel compounds, pharmaceutical compositions, and methods for promoting nerve regeneration, particularly including sympathetic nerve regeneration in the heart following a myocardial infarction and damage to the central nervous system, such as after a cerebrovascular accident, through inhibitory extracellular matrix that includes chondroitin sulfate roteoglycans (CSPG).